increase sedation. Use Caution/Monitor.dobutaminedesipramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dolasetrondesipramine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.donepezildonepezil and desipramine both increase QTc interval. Use Caution/Monitor.dopaminedesipramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dopexaminedesipramine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dosulepindesipramine and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramine and dosulepin both increase sedation. Use Caution/Monitor.doxepindesipramine and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramine and doxepin both increase sedation. Use Caution/Monitor.doxylaminedoxylamine and desipramine both increase sedation. Use Caution/Monitor.dronedaronedronedarone will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.droperidoldroperidol and desipramine both increase sedation. Use Caution/Monitor.duloxetineduloxetine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.efavirenzefavirenz and desipramine both increase QTc interval. Use Caution/Monitor.eletriptaneletriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.eliglustateliglustat increases levels of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.eliglustat and desipramine both increase QTc interval. Use Caution/Monitor.elvitegravir/cobicistat/emtricitabine/tenofovir DFelvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.entrectinibentrectinib and desipramine both increase QTc interval. Use Caution/Monitor.ephedrinedesipramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.desipramine increases effects of ephedrine by unknown mechanism. Use Caution/Monitor.epinephrinedesipramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.desipramine increases effects of epinephrine by unknown mechanism. Use Caution/Monitor.epinephrine inhaleddesipramine and epinephrine inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Tricyclic antidepressants may potentiate epinephrine effect on cardiovascular system.epinephrine racemicdesipramine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.desipramine increases effects of epinephrine racemic by unknown mechanism. Use Caution/Monitor.ergotaminedesipramine and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.eribulineribulin and desipramine both increase QTc interval. Use Caution/Monitor.escitalopramescitalopram increases toxicity of desipramine by QTc interval. Use Caution/Monitor.esketamine intranasalesketamine intranasal, desipramine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.estazolamestazolam and desipramine both increase sedation. Use Caution/Monitor.ethanoldesipramine and ethanol both increase sedation. Use Caution/Monitor.etomidateetomidate and desipramine both increase sedation. Use Caution/Monitor.ezogabineezogabine, desipramine. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.fedratinibfedratinib will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary.fenfluraminedesipramine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.desipramine and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.fenfluramine, desipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome.fingolimodfingolimod and desipramine both increase QTc interval. Use Caution/Monitor.flecainidedesipramine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.fluoxetinedesipramine and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.fluphenazinefluphenazine and desipramine both increase sedation. Use Caution/Monitor.flurazepamflurazepam and desipramine both increase sedation. Use Caution/Monitor.fluvoxaminefluvoxamine and desipramine both increase QTc interval. Modify Therapy/Monitor Closely.formoteroldesipramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.foscarnetdesipramine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.fostemsavirdesipramine and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. frovatriptanfrovatriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.gabapentingabapentin, desipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.gabapentin enacarbilgabapentin enacarbil, desipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.ganaxolonedesipramine and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacingemifloxacin and desipramine both increase QTc interval. Use Caution/Monitor.gilteritinibgilteritinib and desipramine both increase QTc interval. Use Caution/Monitor.glycopyrrolatedesipramine increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor.glycopyrrolate inhaleddesipramine increases levels of glycopyrrolate inhaled by unknown mechanism. Use Caution/Monitor.glycopyrronium tosylate topicalglycopyrronium tosylate topical, desipramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.goserelindesipramine and goserelin both increase QTc interval. Use Caution/Monitor.haloperidolhaloperidol and desipramine both increase sedation. Use Caution/Monitor.henbanehenbane and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.homatropinehomatropine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine Ahuperzine A increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hydrocodonehydrocodone, desipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.hydromorphonehydromorphone and desipramine both increase sedation. Use Caution/Monitor.hydroxyzinehydroxyzine and desipramine both increase sedation. Use Caution/Monitor.hydroxyzine and desipramine both increase QTc interval. Use Caution/Monitor.hyoscyaminehyoscyamine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayhyoscyamine spray and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.ibrutinibdesipramine increases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with moderate CYP3A4 inhibitors, reduce ibrutinib dose to 280 mg qDay (B-cell malignancies) or 420 mg qDay (graft versus host disease). After CYP3A inhibitor discontinuation, resume previous dose of ibrutinib.iloperidonedesipramine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.iloperidone and desipramine both increase sedation. Use Caution/Monitor.imatinibimatinib will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.desipramine will increase the level or effect of imatinib by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.imipraminedesipramine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramine and imipramine both increase sedation. Use Caution/Monitor.indacaterol, inhaledindacaterol, inhaled, desipramine. QTc interval. Use Caution/Monitor. Indacaterol should be administered with extreme caution to patients treated with TCAs. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.ipratropiumipratropium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.isofluraneisoflurane and desipramine both increase QTc interval. Use Caution/Monitor.isoniaziddesipramine and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.isoproterenoldesipramine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.itraconazoleitraconazole and desipramine both increase QTc interval. Use Caution/Monitor.ketamineketamine and desipramine both increase sedation. Use Caution/Monitor.ketotifen, ophthalmicdesipramine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.L-tryptophandesipramine and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.lapatinibdesipramine and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.lasmiditanlasmiditan, desipramine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.desipramine increases effects of lasmiditan by serotonin levels. Use Caution/Monitor. Coadministration may increase risk of serotonin syndrome.lemborexantlemborexant, desipramine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.levalbuteroldesipramine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.levofloxacindesipramine and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.levorphanollevorphanol and desipramine both increase sedation. Use Caution/Monitor.levothyroxinelevothyroxine increases effects of desipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.liothyronineliothyronine increases effects of desipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.liotrixliotrix increases effects of desipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.lisdexamfetaminedesipramine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.desipramine, lisdexamfetamine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue along with concomitant serotonergic drug(s).lithiumdesipramine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.lithium and desipramine both increase QTc interval. Use Caution/Monitor.lofepraminedesipramine and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramine and lofepramine both increase sedation. Use Caution/Monitor.lofexidinedesipramine and lofexidine both increase sedation. Use Caution/Monitor.desipramine decreases effects of lofexidine by unspecified interaction mechanism. Use Caution/Monitor.loprazolamloprazolam and desipramine both increase sedation. Use Caution/Monitor.lorazepamlorazepam and desipramine both increase sedation. Use Caution/Monitor.lorcaserinlorcaserin will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.lormetazepamlormetazepam and desipramine both increase sedation. Use Caution/Monitor.loxapineloxapine and desipramine both increase sedation. Use Caution/Monitor.loxapine inhaledloxapine inhaled and desipramine both increase sedation. Use Caution/Monitor.lsddesipramine and lsd both increase serotonin levels. Modify Therapy/Monitor Closely.lurasidonelurasidone increases effects of desipramine by Other (see comment). Use Caution/Monitor. Comment: Potential for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust dose of antihypertensive agent as needed.maprotilinedesipramine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramine and maprotiline both increase sedation. Use Caution/Monitor.maravirocmaraviroc will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.marijuanamarijuana will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.desipramine and marijuana both increase sedation. Use Caution/Monitor.meclizinemeclizine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.melatonindesipramine and melatonin both increase sedation. Use Caution/Monitor.meperidinemeperidine and desipramine both increase sedation. Use Caution/Monitor.meprobamatedesipramine and meprobamate both increase sedation. Use Caution/Monitor.metaproterenoldesipramine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.metaxalonemetaxalone and desipramine both increase sedation. Use Caution/Monitor.methadonedesipramine and methadone both increase QTc interval. Modify Therapy/Monitor Closely.methadone and desipramine both increase sedation. Use Caution/Monitor.methamphetaminedesipramine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methocarbamolmethocarbamol and desipramine both increase sedation. Use Caution/Monitor.methscopolaminemethscopolamine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.methylenedioxymethamphetaminedesipramine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methylphenidatedesipramine, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.methylphenidate transdermalmethylphenidate transdermal will increase the level or effect of desipramine by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate. midazolammidazolam and desipramine both increase sedation. Use Caution/Monitor.midazolam intranasalmidazolam intranasal, desipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.midodrinedesipramine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.mifepristonemifepristone, desipramine. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.mirabegronmirabegron will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.mirtazapinedesipramine and mirtazapine both increase sedation. Use Caution/Monitor.desipramine and mirtazapine both increase serotonin levels. Modify Therapy/Monitor Closely.modafinildesipramine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.morphinemorphine and desipramine both increase sedation. Use Caution/Monitor.desipramine and morphine both increase serotonin levels. Modify Therapy/Monitor Closely.motherwortdesipramine and motherwort both increase sedation. Use Caution/Monitor.moxonidinedesipramine and moxonidine both increase sedation. Use Caution/Monitor.nabilonedesipramine and nabilone both increase sedation. Use Caution/Monitor.nalbuphinenalbuphine and desipramine both increase sedation. Use Caution/Monitor.naldemedinedesipramine increases levels of naldemedine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor naldemedine for potential adverse effects if coadministered with strong or moderate CYP3A4 inhibitors.naratriptannaratriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.nefopamnefopam, desipramine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Use combination with caution.nelfinavirnelfinavir will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.nilotinibnilotinib will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.norepinephrinedesipramine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.desipramine increases effects of norepinephrine by unknown mechanism. Use Caution/Monitor.nortriptylinedesipramine and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramine and nortriptyline both increase